IL299308A - Topical formulations of (1s)-1-phenyl-2-pyridin-2-ylethanamine - Google Patents
Topical formulations of (1s)-1-phenyl-2-pyridin-2-ylethanamineInfo
- Publication number
- IL299308A IL299308A IL299308A IL29930822A IL299308A IL 299308 A IL299308 A IL 299308A IL 299308 A IL299308 A IL 299308A IL 29930822 A IL29930822 A IL 29930822A IL 299308 A IL299308 A IL 299308A
- Authority
- IL
- Israel
- Prior art keywords
- ylethanamine
- pyridin
- phenyl
- cutaneous
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063043075P | 2020-06-23 | 2020-06-23 | |
| PCT/US2021/038564 WO2021262779A1 (en) | 2020-06-23 | 2021-06-23 | Topical formulations of (1s)-1-phenyl-2-pyridin-2-ylethanamine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL299308A true IL299308A (en) | 2023-02-01 |
Family
ID=79281832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL299308A IL299308A (en) | 2020-06-23 | 2021-06-23 | Topical formulations of (1s)-1-phenyl-2-pyridin-2-ylethanamine |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12564579B2 (https=) |
| EP (1) | EP4168116A4 (https=) |
| JP (1) | JP2023531918A (https=) |
| KR (1) | KR20230026449A (https=) |
| CN (1) | CN115836052A (https=) |
| AU (1) | AU2021297823A1 (https=) |
| BR (1) | BR112022025900A2 (https=) |
| CA (1) | CA3187140A1 (https=) |
| IL (1) | IL299308A (https=) |
| MX (1) | MX2022016183A (https=) |
| PH (1) | PH12022553502A1 (https=) |
| WO (1) | WO2021262779A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024220093A2 (en) * | 2023-04-20 | 2024-10-24 | LifeActive, Inc. | Transdermal delivery formulations and methods for the manufacture thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0594729A1 (en) * | 1991-07-17 | 1994-05-04 | Pfizer Inc. | 2-(4-hydroxypiperidino)-1-alkanol derivatives as antiischemic agents |
| DE69317411T2 (de) | 1992-04-03 | 1998-07-30 | Ab Astra, Soedertaelje | Enantiomere 1-phenyl-2-(2-pyridinyl)ethylamin für die behandlung neurodegenerativer störungen |
| US20040082543A1 (en) * | 2002-10-29 | 2004-04-29 | Pharmacia Corporation | Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain |
| RS58991B1 (sr) | 2013-11-05 | 2019-08-30 | Astrazeneca Ab | Prolekovi nmda antagonista |
| US11358935B2 (en) | 2016-11-28 | 2022-06-14 | Biohaven Pharmaceutical Holding Company Ltd. | Prodrugs of lanicemine and their method of use |
| US12090145B2 (en) * | 2018-08-20 | 2024-09-17 | Yale University | Combination therapy for treating or preventing depression or other mood diseases |
-
2021
- 2021-06-23 IL IL299308A patent/IL299308A/en unknown
- 2021-06-23 AU AU2021297823A patent/AU2021297823A1/en not_active Abandoned
- 2021-06-23 JP JP2022578615A patent/JP2023531918A/ja not_active Withdrawn
- 2021-06-23 MX MX2022016183A patent/MX2022016183A/es unknown
- 2021-06-23 PH PH1/2022/553502A patent/PH12022553502A1/en unknown
- 2021-06-23 BR BR112022025900A patent/BR112022025900A2/pt not_active Application Discontinuation
- 2021-06-23 EP EP21829394.2A patent/EP4168116A4/en active Pending
- 2021-06-23 US US17/923,585 patent/US12564579B2/en active Active
- 2021-06-23 CN CN202180044182.0A patent/CN115836052A/zh active Pending
- 2021-06-23 KR KR1020237001959A patent/KR20230026449A/ko not_active Withdrawn
- 2021-06-23 CA CA3187140A patent/CA3187140A1/en active Pending
- 2021-06-23 WO PCT/US2021/038564 patent/WO2021262779A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021262779A1 (en) | 2021-12-30 |
| EP4168116A4 (en) | 2024-07-10 |
| AU2021297823A1 (en) | 2023-02-16 |
| KR20230026449A (ko) | 2023-02-24 |
| US20230190719A1 (en) | 2023-06-22 |
| EP4168116A1 (en) | 2023-04-26 |
| CA3187140A1 (en) | 2021-12-30 |
| US12564579B2 (en) | 2026-03-03 |
| JP2023531918A (ja) | 2023-07-26 |
| MX2022016183A (es) | 2023-02-13 |
| PH12022553502A1 (en) | 2024-04-22 |
| BR112022025900A2 (pt) | 2023-01-10 |
| CN115836052A (zh) | 2023-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282995A (en) | Lipid nanoparticle formulations | |
| MA50205A (fr) | Formulation de nicotine | |
| EP4244818A4 (en) | Disambiguation of poses | |
| EP4444240A4 (en) | AXILLARY CRUTCH | |
| IL281976A (en) | Anti-fgfr2 antibody formulations | |
| IL280047A (en) | Formulation of cannabinoid compounds | |
| MX2019011613A (es) | Formulaciones de acido 1-amino-1-ciclopropanocarboxilico. | |
| EP4003323A4 (en) | STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES | |
| MX2020006016A (es) | Polimorfos. | |
| EP3810118A4 (en) | FORMULATIONS OF TEGAVIVINT AND RELATED COMPOUNDS | |
| IL285765A (en) | Therapeutic uses of dulaglutide | |
| IL305851A (en) | Preparation of 2-chloro-4-fluoro-5-nitrobenzoic acid | |
| IL299308A (en) | Topical formulations of (1s)-1-phenyl-2-pyridin-2-ylethanamine | |
| EP4284362A4 (en) | Formulations | |
| IL288813A (en) | Stable intranasal formulations of carbetocin | |
| IL307342A (en) | Formulations of apremilast | |
| IL285119A (en) | Use of spiropidion | |
| CR20240192A (es) | Composiciones farmacéuticas de efruxifermina | |
| DK3790529T3 (da) | Formulering omfattende aktivt oxygen | |
| IL310652A (en) | Formulations of radiprodil | |
| EP4062913C0 (en) | SOLID ORAL FORMULATION OF UTIDELONE | |
| EP4188088A4 (en) | Formulations | |
| CR20220587A (es) | Formulaciones farmacéuticas | |
| EP4395765A4 (en) | INTRAVENOUS FORMULATIONS OF RK-33 | |
| PL3879173T3 (pl) | Zestaw komponentów zasilanych prądem |